Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · All outcomes

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 6 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Amoxicillin + metronidazole + SRP vs Supragingival scaling (plus placebo)

Adverse events due to periodontal therapy · People with periodontitis and metabolic syndrome (no CVD; primary prevention)

It is very uncertain whether scaling and root planing (SRP) plus antibiotics (amoxicillin and… changes adverse events due to periodontal therapy compared with supragingival scaling (plus placebo) (very low certainty).

1 finding from 1 review

Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes
12 months
Peto OR 0.14 [0.00, 6.90]
1 study · 165 participants
Very low

Amoxicillin + metronidazole + SRP vs Supragingival scaling (plus placebo)

Cardiovascular events · People with periodontitis and metabolic syndrome (no CVD; primary prevention)

It is very uncertain whether scaling and root planing (SRP) plus antibiotics (amoxicillin and… changes all cardiovascular events compared with supragingival scaling (plus placebo) (very low certainty).

1 finding from 1 review

Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes
12 months
Peto OR 7.77 [1.07, 56.1]
1 study · 165 participants
Very low

Amoxicillin + metronidazole + SRP vs Supragingival scaling (plus placebo)

All CVD-related death · People with periodontitis and metabolic syndrome (no CVD; primary prevention)

It is very uncertain whether scaling and root planing (SRP) plus antibiotics (amoxicillin and… changes all CVD-related death compared with supragingival scaling (plus placebo) (very low certainty).

1 finding from 1 review

Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes
12 months
Peto OR 7.48 [0.15, 376.98]
1 study · 165 participants
Very low

Amoxicillin + metronidazole + SRP vs Supragingival scaling (plus placebo)

All‐cause death · People with periodontitis and metabolic syndrome (no CVD; primary prevention)

It is very uncertain whether scaling and root planing (SRP) plus antibiotics (amoxicillin and… changes all-cause death compared with supragingival scaling (plus placebo) (very low certainty).

1 finding from 1 review

Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes
12 months
Peto OR 7.48 [0.15, 376.98]
1 study · 165 participants
Very low

Amoxicillin + metronidazole + SRP vs Supragingival scaling (plus placebo)

CRP (mg/dL) at end of study · People with periodontitis and metabolic syndrome (no CVD; primary prevention)

1 finding from 1 review

Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes
12 months
beta coefficient -0.002 [-0.19, 0.20]
1 study
Very low

Amoxicillin + metronidazole + SRP vs Supragingival scaling (plus placebo)

Fibrinogen · People with periodontitis and metabolic syndrome (no CVD; primary prevention)

1 finding from 1 review

Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes
12 months
beta coefficient 10.9 [-12.0, 33.8]
1 study
Very low